MedTrace Logo

MB-105 in Patients With CD5 Positive T-cell Lymphoma

NCT06534060 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-10-03

No results posted yet for this study

Summary

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.

Conditions

  • Lymphoma, T-Cell

Interventions

BIOLOGICAL

Genetic: MB-105

MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.

Sponsors & Collaborators

  • March Biosciences Inc

    lead INDUSTRY

Principal Investigators

  • Alice Bexon, MD, CMO · March Bio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-15
Primary Completion
2028-02-29
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06534060 on ClinicalTrials.gov